Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion type Assertion NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_head.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion description "[The PI3K/mammalian Target of Rapamycin (mTOR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therapeutic target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion evidence source_evidence_literature NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion SIO_000772 24133218 NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion wasDerivedFrom befree-20150227 NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.
- NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_assertion wasGeneratedBy ECO_0000203 NP625112.RAQlrWQ_9FTCpNpxev3Dy52Te-ohWS1sX3GKh61fAQmgw130_provenance.